EC 0652
Alternative Names: 99mTc-EC0652; DUPA-99mTc; EC 1169 companion diagnostic - Endocyte; EC0652; Technetium Tc99m PSMA targeting-agentsLatest Information Update: 28 Nov 2021
Price :
$50 *
At a glance
- Originator Endocyte
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for phase-I development in Prostate-cancer(Diagnosis) in USA
- 21 Dec 2018 Endocyte has been acquired by Novartis
- 29 Nov 2018 Endocyte completes a phase I trial for Prostate cancer (late-stage disease, recurrent, Second-line therapy or greater)in USA (IV) (NCT02202447)